<?xml version="1.0" encoding="UTF-8"?>
<ref id="B17">
 <label>17.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Luo</surname>
    <given-names>P</given-names>
   </name>, 
   <name name-style="western">
    <surname>Liu</surname>
    <given-names>Y</given-names>
   </name>, 
   <name name-style="western">
    <surname>Qiu</surname>
    <given-names>L</given-names>
   </name>, 
   <name name-style="western">
    <surname>Liu</surname>
    <given-names>X</given-names>
   </name>, 
   <name name-style="western">
    <surname>Liu</surname>
    <given-names>D</given-names>
   </name>, 
   <name name-style="western">
    <surname>Li</surname>
    <given-names>J</given-names>
   </name>
  </person-group>
  <year>2020</year>
  <article-title>Tocilizumab treatment in COVID‐19: a single center experience</article-title>. 
  <source>J Med Virol</source>
  <volume>92</volume>:
  <fpage>814</fpage>–
  <lpage>818</lpage>. doi:
  <pub-id pub-id-type="doi">10.1002/jmv.25801</pub-id>.
  <pub-id pub-id-type="pmid">32253759</pub-id>
 </mixed-citation>
</ref>
